These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37270384)

  • 1. Future Directions in the Frontline Management of Waldenström Macroglobulinemia.
    Buske C; Palomba ML
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):719-725. PubMed ID: 37270384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report of consensus panel 1 from the 11
    Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
    Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.
    Migkou M; Fotiou D; Gavriatopoulou M; Dimopoulos MA
    Expert Opin Drug Saf; 2021 Sep; 20(9):987-995. PubMed ID: 34137347
    [No Abstract]   [Full Text] [Related]  

  • 4. How to manage waldenström's macroglobulinemia in 2024.
    Grunenberg A; Buske C
    Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
    Varettoni M; Matous JV
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
    Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
    Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
    Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
    Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Waldenström's macroglobulinemia].
    Watanabe R
    Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia.
    Buske C
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):821-827. PubMed ID: 30190020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
    Grunenberg A; Buske C
    Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.
    Leblond V; Kastritis E; Advani R; Ansell SM; Buske C; Castillo JJ; García-Sanz R; Gertz M; Kimby E; Kyriakou C; Merlini G; Minnema MC; Morel P; Morra E; Rummel M; Wechalekar A; Patterson CJ; Treon SP; Dimopoulos MA
    Blood; 2016 Sep; 128(10):1321-8. PubMed ID: 27432877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
    Kapoor P; Paludo J; Abeykoon JP
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM).
    Chiappella A; Ciochetto C; Orsucci L; Vitolo U
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):149-51. PubMed ID: 21454219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety profile of medications used to treat Waldenström's macroglobulinemia.
    García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
    Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approach to Waldenström Macroglobulinemia.
    Ravi G; Kapoor P
    Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
    Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
    Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing Waldenström's macroglobulinemia with BTK inhibitors.
    Buske C; Jurczak W; Salem JE; Dimopoulos MA
    Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.